Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

oche through a global development and commercialization agreement.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the Company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements related to the further development and potential safety, efficacy, commercialization and other characteristics of tanespimycin, Kosan's development plans with respect to tanespimycin, including but not limited to Kosan's plans and timing for the initiation of the TIME-1 trial and TIME-2 as a potential registration trial, and the FDA's later review of the results of the TIME-1 clinical trial. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, risks related to the development of tanespimycin, including the risk that studies and ongoing trials may not demonstrate safety and efficacy sufficient to initiate additional clinical trials, continue clinical development on the timing currently anticipated or at all, obtain the requisite regulatory approvals or result in a marketable product; risks related to regulatory requirements and other risks detailed from time to time in the Kosan's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward- looking statements.

'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... December 17 ,Agendia, a world leader in ... and Drug Administration (FDA) cleared its MammaPrint breast,cancer ... only FDA-cleared,breast cancer recurrence test available to patients ... has issued four clearances for MammaPrint, covering,all aspects ... "This FDA clearance, along with our recently ...
(Date:12/17/2009)... SAN DIEGO, Dec. 17 Suneva Medical, ... that it has signed a multi-million dollar line ... The line of credit facility will be ... only FDA-approved microsphere-enhanced collagen dermal filler on the ... Aesthetic Market growth objectives. ,, "Today Suneva Medical ...
(Date:12/17/2009)... 17 Instacare Corp. (OTC Bulletin Board: ... life-enhancing prescription drugs and diagnostics and at home ... leading developer and provider of e-health technologies and ... today that as part of the preparation of ... to add two new Directors and has rejected, ...
Breaking Medicine Technology:FDA Broadens Clearance for Agendia's MammaPrint(R) 2Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 2Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 3Instacare Corp. Board of Directors Sets Growth Plans for 2010 2Normal cells far from cancer give nanosignals of trouble 9146 1Normal cells far from cancer give nanosignals of trouble 9146 2Normal cells far from cancer give nanosignals of trouble 9146 3Playing it safe 9143 1Claimsnet Announces Claims Processing Agreement With New Health Care Solutions Company 50956 1Claimsnet Announces Claims Processing Agreement With New Health Care Solutions Company 50956 2
(Date:12/17/2009)... help lengthen long bones in the arms and legs in order ... Because the device is completely internal, patients can remain mobile while ... , ... (PRWEB) December 17, 2009 -- ... at Park Meadows Cosmetic Surgery in Lone Tree, Colorado, ...
(Date:12/17/2009)... Dec. 17 Fred Hutchinson Cancer Research ... D.S.c., has been awarded the distinction of AAAS ... bestowed upon members of the American Association for ... peers. ,, Halloran is a researcher in the ... a professor of biostatistics at the University of ...
(Date:12/17/2009)... Blue Shield of Michigan announced today that Kevin Klobucar, ... current vice president for products and marketing, will succeed ... maintenance organization when Carlson retires at the end of ... Daniel J. Loepp, president and CEO of BCBSM, parent ... pending formal approval from the BCBSM and BCN boards ...
(Date:12/17/2009)... short-term effect may not be beneficial , , THURSDAY, Dec. ... researchers report that the immediate effect of the fish ... is a short-term increase in blood fats and the ... surprised to find that the acute response has some ... expect from chronic, long-term intake," said Lindsay E. Robinson, ...
(Date:12/17/2009)... to try alcohol, illegal drugs , , THURSDAY, Dec. 17 ... is riskier than using illicit drugs or binge drinking, ... increase the likelihood that they,ll experiment with alcohol or ... on the right track with cigarette smoking and need ... of other substances," Pamela S. Hyde, administrator of the ...
Breaking Medicine News(10 mins):Health News:Patent Granted on GenerOs EX, A Medical Device That Helps Bones Grow 2Health News:Patent Granted on GenerOs EX, A Medical Device That Helps Bones Grow 3Health News:M. Elizabeth Halloran Named AAAS Fellow 2Health News:M. Elizabeth Halloran Named AAAS Fellow 3Health News:M. Elizabeth Halloran Named AAAS Fellow 4Health News:Could Omega-3s Boost Blood Fat Levels? 2Health News:Teens Think Smoking More Dangerous Than Drinking, Drugs 2
... and Broader Kidney Care Community,in partnership with the Forum, ... Kidney Care Partners (KCP) - an ... manufacturers working together to improve quality of care for ... - today expressed alarm regarding the racial disparity among ...
... Underway, On-lineBALTIMORE, March 3 Maryland breast cancer patients ... angel on their sides: The Red Devils (TRD), ... quality of life for Maryland breast cancer patients and ... suburban D.C. area are Doctor,s Community Hospital, Holy ...
... Chester Santos Trains to Defend His TitleNORTHRIDGE, Calif., March ... 99 faces and names, two decks of shuffled playing ... a matter of minutes. Chester Santos, the 2008 USA ... challenges, among others, when he defends his title at ...
... Highland Good Steward Management ("HGSM") today announced it ... investment adviser, as a sub adviser to Highland ... HGSM focuses on incorporating environmental, social ... William "Doug" Douglass III, co-founder of K2, said, ...
... may significantly improve the safety of methadone, a drug ... heroin and other opioid drugs, according to researchers at ... the University of Washington in Seattle. , The researchers ... believed. Those incorrect assumptions about methadone have been making ...
... disease is a typical example of a malabsorption ... including folate and vitamin B12. Hyperhomocysteinemia is significantly ... disease than healthy controls. , A research team ... the effect of vitamin B6, folate, and vitamin ...
Other Medicine News:Health News:Kidney Care Partners Raises Alarm on Racial Disparities in Kidney Disease; Joins With National Minority Quality Forum to Educate Public, Congress During National Kidney Month 2Health News:Kidney Care Partners Raises Alarm on Racial Disparities in Kidney Disease; Joins With National Minority Quality Forum to Educate Public, Congress During National Kidney Month 3Health News:Red Devils Expand Into Suburban DC, Receive National Komen Grant 2Health News:The Making of a Memory Champion 2Health News:The Making of a Memory Champion 3Health News:K2 Advisors Named Investment Advisor by Highland Good Steward Management 2Health News:New information points to safer methadone use for treatment of pain and addiction 2Health News:New information points to safer methadone use for treatment of pain and addiction 3Health News:New information points to safer methadone use for treatment of pain and addiction 4Health News:Are vitamin supplements effective in celiac disease patients? 2
... immunoassay system built around the many positive ... important addition of Logic Driven Incubation (LDI). ... for optimal performance with the fastest possible ... such as the cardiac biomarkers and HCG ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
... for the quantitative determination of C-peptide in ... Automatic Immunoassay System. C-peptide measurement is used ... patients treated with insulin, to distinguish between ... various other diagnostic applications in patients with ...
... Multifocal IOL was designed to provide a ... glasses in most situations. While distance vision ... to that of a single vision monofocal ... and about 19 in 20 people with ...
Medicine Products: